The risk of infections in patients with myelodysplastic syndromes in 2016.

about

Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.Monocyte function in patients with myelodysplastic syndrome.

P2860

Q47205373-50103EA7-A8CF-4884-99AB-8C8160FE58CC Q52719307-87CF36F6-DC9C-421D-9252-B2C9B9AB8241

P2860

The risk of infections in patients with myelodysplastic syndromes in 2016.

Item

http://www.wikidata.org/entity/Q38813702

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

The risk of infections in patients with myelodysplastic syndromes in 2016.

@en

type

Item

label

The risk of infections in patients with myelodysplastic syndromes in 2016.

@en

prefLabel

The risk of infections in patients with myelodysplastic syndromes in 2016.

@en

P1476

The risk of infections in patients with myelodysplastic syndromes in 2016.

@en

P2093

Corrado Girmenia

http://www.w3.org/2001/XMLSchema#string

Morena Caira

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management

Infections in myelodysplastic syndromes

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.

Myelodysplastic syndromes: Contemporary review and how we treat.

The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients.

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.

Iron and microbial infection.

P304

607-614

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17474086.2016.1181540

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Roberto Latagliata

P577

2016-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27100058

http://www.w3.org/2001/XMLSchema#string

The risk of infections in patients with myelodysplastic syndromes in 2016.

about

P2860

P2860

The risk of infections in patients with myelodysplastic syndromes in 2016.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698